Insider Trading Pulse — July 09, 2026

CEO Wei Che-Chia and 23 other top executives collectively bought 1,350 shares at $76.62 (~$103K total). This is the single most concentrated insider buying event of the day, with 100% of reported TSMC transactions being purchases. The breadth of buying across the C-suite (CEO, Co-COOs, CFO, SVPs, VPs) signals unified management conviction in the company's valuation and outlook.

Chairman & CEO Michael J. Farrell sold 4,991 shares at $218.55 (~$1.09M) after exercising options at $146.34. While executed under a 10b5-1 plan (reducing directional signal), the $1.09M sale is the largest single insider disposition of the day. The sale price ($218.55) represents a 49% gain from the exercise price, suggesting profit-taking at elevated levels.

President & CEO Xingjuan Chao sold 23,554 shares at $19.90 (~$469K) across 7 transactions, also under a 10b5-1 plan. This is the second-largest insider sale of the day. The CEO exercised 1,446 options at $4.70 and immediately sold at $19.90, capturing a 323% gain. The aggressive selling by the top executive warrants caution despite the 10b5-1 structure.

CEO Brent Guerisoli exercised 6,249 options at $4.54 (~$28.4K) and sold 3,165 shares at $40.51 (~$128K). The exercise-to-sale pattern (selling 51% of exercised shares) suggests the CEO is monetizing equity while retaining a meaningful stake. The sale at 8.9x the exercise price indicates significant profit-taking.

Director Pablo Lagos Espinosa sold 10,000 shares at $35.54 (~$355K) under a 10b5-1 plan. This is a notable director-level sale at a company with a market cap of ~$1.5B. The sale represents ~4.6% of the director's disclosed holdings, a material reduction.

Vice President Jeffrey Sarti bought 12,242.9 shares at $10.21 (~$125K), the largest insider purchase of the day by value. This is a significant vote of confidence from a senior officer in a closed-end fund, suggesting the VP sees value at the current price.

CTO Li Tianmin sold 2,518 shares at $67.45 (~$170K), while Director Liu Chun sold 174 shares at $67.31 (~$11.7K). Two insiders selling on the same day at similar prices suggests coordinated profit-taking or a lack of near-term catalysts.

CEO Omer David Keilaf disposed of 679,400 ordinary shares plus 852,630 share options. This is the largest insider disposition by volume of the day, though the filing does not specify sale price or 10b5-1 status. The massive option disposal by the CEO is a significant bearish signal for this lidar company.

Director Stephen K. Brannan bought 1,000 shares at $2.03 (~$2.03K). While small in absolute terms, this open-market purchase by a director at a micro-cap biotech trading near $2 signals insider belief in the company's prospects at current levels.

Two executives (CFO Elley and SVP Dozier) had shares withheld for taxes after exercising options. CFO Elley exercised 6,300 options at $11.71 and had 4,924 shares withheld at $16.95 (~$83.5K). SVP Dozier exercised 5,550 options and had 2,671 shares withheld (~$45.3K). These are routine tax-withholding transactions, not directional signals.

CEO Omer David Keilaf disposed of 1.53 million total securities (679,400 shares + 852,630 options). This represents a near-complete liquidation of the CEO's option position. Without a 10b5-1 plan disclosed, this raises serious questions about management's confidence in the company's trajectory.

CEO Farrell sold $1.09M at $218.55, capturing a 49% gain from his option exercise price. ResMed trades at ~30x forward earnings. Insider selling at elevated multiples, even under 10b5-1, is a risk factor for momentum investors.

CEO Chao sold $469K in a single day, exercising deep-in-the-money options ($4.70 strike) and immediately selling at $19.90. For a company that likely IPO'd recently (implied by low option strike), insider selling so soon after listing is a red flag for new investors.

CEO Guerisoli exercised options at $4.54 and sold at $40.51, an 8.9x gain. While he retained 50% of exercised shares, the pattern of exercising and immediately selling suggests the CEO is de-risking personal exposure at current prices.

Director Espinosa sold $355K under 10b5-1, but no corresponding option exercise was reported. This suggests the sale was from existing holdings, not a planned monetization of options. Director-level sales of this magnitude without a clear reinvestment signal are cautionary.

Both CTO Li and Director Liu sold shares on the same day. While the amounts are modest relative to their holdings, the coordination in timing (same day, similar prices) suggests a potential lack of positive near-term catalysts.

EVP Taylor sold 2,165 shares ($41.1K) and CAO Tam sold 68 shares ($1.29K), both under 10b5-1 plans. While small, the pattern of multiple insiders selling at the same price ($19.00) suggests pre-planned selling that could continue.

Two EVPs were awarded 17,000 shares total ($182K) as compensation. While not a sale, large equity grants can dilute existing shareholders. The stock price used ($9.97 and $11.17) is near 52-week lows for many regional banks, suggesting retention awards rather than performance-based incentives.

24 insiders (CEO, 2 Co-COOs, CFO, 20 VPs/SVPs) all bought shares at $76.62 on the same day. This is the strongest insider buying signal in the entire dataset. For a $750B+ market cap company, such coordinated buying is extremely rare and suggests management sees the stock as undervalued. TSMC trades at ~18x forward earnings vs. 25x for the SOX index.

VP Sarti's $125K purchase at $10.21 is the largest insider buy of the day. For a closed-end fund, insider buying is a strong signal that the fund's assets are undervalued relative to the market price. Investors should examine the fund's discount to NAV.

Director Brannan bought 1,000 shares at $2.03. For a micro-cap biotech, an open-market director purchase (not an award) is a meaningful signal. The $2.03 price point could represent a floor if the director is willing to add at these levels.

CFO Elley exercised 6,300 options at $11.71 and retained 1,376 shares after tax withholding. SVP Dozier exercised 5,550 options and retained 2,879 shares. Both executives chose to pay taxes with shares rather than sell all exercised options, indicating they want to maintain or increase their equity stakes.

Director Zaccardelli was awarded 42,658 stock options. While not a purchase, the size of the award (42,658 options) suggests the board is incentivizing the director with significant upside potential. For a biotech, large option grants often precede catalyst-rich periods.

Director Paul was awarded 89,058 RSUs. This large equity grant aligns the director's interests with long-term shareholders. Yext trades at ~1.5x revenue, and insider awards of this magnitude suggest the board is focused on retention and performance.

Director Herbst was awarded 661 shares total ($18.8K) as compensation. For a small-cap bank, director compensation in stock (not cash) signals board-level commitment to shareholder alignment.

EVP Gephart sold only 15 shares ($1.07K). This is a rounding error relative to her 946-share remaining holdings. The sale is likely for tax purposes and should not be interpreted as a bearish signal. [OPPORTUNITY - False Signal]

TSMC's 24-insider buying event is the dominant theme of the day. In a sector facing cyclical headwinds and geopolitical uncertainty, unified insider buying at the world's largest foundry signals that management sees trough valuation. This contrasts with the broader tech sell-off narrative and suggests TSMC's AI-driven growth trajectory is intact.

Three healthcare companies (ResMed, Ceribell, Pennant Group) saw CEOs sell shares after exercising deep-in-the-money options. The pattern of exercise-and-sell at significant gains (49% to 323%) suggests healthcare executives are taking profits at elevated valuations. This is a sector-level caution signal for medtech and healthcare services.

The most notable insider purchases (83 Investment Group, Serina Therapeutics) were in small-cap or micro-cap names. This aligns with historical patterns where insider buying concentrates in smaller companies where management has better visibility into near-term catalysts. The TSMC buying is the exception that proves the rule.

All material insider sales (ResMed, Ceribell, Pennant, EZCORP, Velocity Financial) were executed under Rule 10b5-1 trading plans. While this reduces the directional signal, the concentration of 10b5-1 selling across multiple sectors suggests insiders are systematically de-risking after the 2023-2025 market rally.

Regional banks (First US Bancshares, Citizens Financial Services, GBank) showed mostly neutral activity (tax withholdings, awards). The lack of open-market buying or selling in financials suggests insiders are waiting for more clarity on interest rate policy and loan growth before making directional bets.

CEO's 1.53M share/option disposal is a major red flag. Watch for Q2 2026 earnings (expected Aug 2026) for any guidance changes or business updates that could explain the CEO's decision to liquidate options.

CEO's $1.09M sale under 10b5-1. Watch for the company's next earnings report (expected late July 2026) for commentary on CPAP demand trends and GLP-1 drug impact on sleep apnea treatment.

CEO's $469K sale post-option exercise. As a recent IPO, watch for the lock-up expiration date and any insider selling that follows. The company's next earnings call will be critical for assessing the CEO's confidence level.

The 24-insider buying event is unprecedented. Watch for any additional insider filings in the coming weeks to see if buying continues. TSMC's Q2 2026 earnings call (expected July 18, 2026) will provide context on whether the buying was opportunistic or fundamentals-driven.

CEO's exercise-and-sale pattern. Watch for the company's Q2 2026 earnings (expected early August 2026) to see if the CEO's profit-taking was justified by results or if it was a warning sign.

Director's $355K sale under 10b5-1. Watch for any additional director or officer sales in the coming weeks. The company's next earnings report will clarify if the sale was related to company-specific issues or broader sector concerns.

Dual insider selling by CTO and Director. Watch for any additional insider sales, particularly by the CEO or CFO. The company's Q2 2026 earnings (expected August 2026) will be key to assessing whether the selling was justified.